Keywords
blast crisis
plasmacytoid dendritic cells
megakaryoblastic
How to Cite
Abstract
Blastic crisis (BC) remains the main challenge in chronic myeloid leukemia (CML). Treatment typically involves a tyrosine kinase inhibitor (TKI) alone or in combination with polychemotherapy, followed by hematopoietic stem cell transplantation (HSCT) for eligible patients. The leukemic phenotype includes both myeloid and lymphoid lineages. Myeloid BC with megakaryocytic differentiation is rare, while differentiation to plasmacytoid dendritic cells is extremely uncommon in the literature. We present a patient with CML in megakaryoblastic blastic crisis (BC-MGK) and a case of blastic crisis with plasmacytoid dendritic cells (BC-PDC), both of whom received combined treatments with TKI and polychemotherapy with excellent outcomes despite the poor prognosis.
References
Khoury JD, Solary E, Abla O y col. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. Leukemia. 2022 Jul;36(7):1703-1719. doi: 10.1038/s41375-022-01613-1.
Baccarani M, Deininger MW, Rosti G y col. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013;122:872-884.
Hochhaus A, Baccarani M, Silver RT y col. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020 Apr;34(4):966-984. doi: 10.1038/s41375-020-0776-2.
Arber DA, Orazi A, Hasserjian R y col. The 2016 revisión to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391-2405.
Arber DA, Brunning RD, Orazi A, y col. Acute myeloid leukaemia, NOS. In: Swerdlow SH, Campo E, Harris NL, et al., eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: International Agency for Research on Cancer; 2017:156-168.
Giri S, Pathak R, Prouet P, Li B, Martin MG. Acute megakaryocytic leukemia is associated with worse outcomes than other types of acute myeloid leukemia. Blood. 2014;124(25):3833-3834.
Teyssier AC, Lapillonne H, Pasquet M y col. Acute megakaryoblastic leukemia (excluding Down syndrome) remains an acute myeloid subgroup with inferior outcome in the French ELAM02 trial. Pediatr Hematol Oncol. 2017;34(8):425-427.
Pullarkat ST, Vardiman JW, Slovak ML y col. Megakaryocytic blast crisis as a presenting manifestation of chronic myeloid leukemia. Leuk Res. 2008 Nov;32(11):1770-5. doi: 10.1016/j.leukres.2008.02.025.
Chisholm KM, Smith J, Heerema-McKenney AE y col. Pathologic, cytogenetic, and molecular features of acute myeloid leukemia with megakaryocytic differentiation: A report from the Children's Oncology Group. Pediatr Blood Cancer. 2023 May;70(5):e30251. doi: 10.1002/pbc.30251.
Bryant BJ, Alperin JB, Elghetany MT. Paraplegia as the presenting manifestation of extramedullary megakaryoblastic transformation of previously undiagnosed chronic myelogenous leukemia. Am J Hematol. 2007;82:150-4.
Pelloso LAF, Baiocchi OCG, Chauffaille MLLF y col. Megakaryocytic blast crisis as a first presentation of chronic myeloid leukemia. Eur J Haematol. 2002;69:58- 61.
Wu CD, Medeiros LJ, Miranda RNy col. Chronic myeloid leukemia manifested during megakaryoblastic crisis. South Med J. 1996;89:422-7.
Campiotti L, Grandi AM, Biotti MG y col. Megakaryocytic blast crisis as first presentation of chronic myeloid leukemia. Am J Hematol. 2007;82:231-3.
Karkuzhali P, Shanthi V, Usha T. A case of chronic myeloid leukaemia presenting as megakaryocytic blast crisis (AML M7). Ecancermedicalscience. 2013 Nov 21;7:375. doi: 10.3332/ecancer.2013.375.
Khemka R, Gupta M, Jena NK. CML with Megakaryocytic Blast Crisis: Report of 3 Cases. Pathol Oncol Res. 2019 Jul;25(3):1253-1258. doi: 10.1007/s12253-018-0484-7.
Kashima E, Nakano E, Watanabe Y y col. Acute Megakaryoblastic Leukemia Harboring a Subclone Expressing BCR-ABL1 Fusion Gene Product. Intern Med. 2021 Nov 15;60(22):3609-3614.
Pemmaraju N, Kantarjian H, Sweet K y col. North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: position on standards of care and areas of need. Blood. 2023 Feb 9;141(6):567-578. doi: 10.1182/blood.2022017865.
Lee YJ, Kim Y, Park SH, Jo JC. Plasmacytoid dendritic cell neoplasms. Blood Res. 2023 Apr 30;58(S1):90-95. doi: 10.5045/br.2023.2023052.
Adams RL, McCarthy C, Bird RJ. Philadelphia chromosome- positive blastic plasmacytoid dendritic cell leukemia. Cancer Genet Cytogenet. 2009 Dec;195(2):186-8. doi: 10.1016/j.cancergencyto.2009.08.012.
Suzuki H, Takeshita M, Hirai R y col. Blastic Plasmacytoid Dendritic Cell Neoplasm Developed in Chronic Myeloid Leukemia in Molecular Remission During a Four-Year Treatment-Free Interval After Six Years of Dasatinib Treatment. Cureus. 2024 Jun 8;16(6):e61944. doi: 10.7759/cureus.61944.
Shah NP, Bhatia R, Altman JK y col. Chronic Myeloid Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2024 Feb;22(1):43-69. doi: 10.6004/jnccn.2024.0007.
Brioli A, Lomaia E, Fabisch C y col. Management and outcome of patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era - analysis of the European LeukemiaNet Blast Phase Registry.
Leukemia. 2024 May;38(5):1072-1080. doi: 10.1038/s41375-024-02204-y.
Copland M. Treatment of blast phase chronic myeloid leukaemia: A rare and challenging entity. Br J Haematol. 2022 Dec;199(5):665-678. doi: 10.1111/bjh.18370.
All material published in the journal HEMATOLOGÍA (electronic and print version) is transferred to the Argentinean Society of Hematology. In accordance with the copyright Act (Act 11 723), a copyright transfer form will be sent to the authors of approved works, which has to be signed by all the authors before its publication. Authors should keep a copy of the original since the journal is not responsible for damages or losses of the material that was submitted. Authors should send an electronic version to the email: revista@sah.org.ar